Navigation Links
Frost & Sullivan Presents bitop AG with the 2013 New Product Innovation Award in the Extremolytes Therapeutics Market

LONDON, June 20, 2013 /PRNewswire/ -- Based on its recent research on the extremolytes therapeutics market, Frost & Sullivan presents bitop AG with the 2013 European Frost & Sullivan Award for New Product Innovation. The company's path-breaking extremolyte platform enables a naturally-derived treatment for atopic dermatitis, allergic rhinitis and conjunctivitis, dry eye or dry nose syndrome, and respiratory diseases. The ready-to-adopt Ectoin®Allergy product line is expected to revolutionize how allergies are treated.

Ectoin® is one of the best studied natural extremolytes and occurs in different microorganisms. This natural compound helps extremophilic microorganisms to survive under harsh conditions. Ectoin® is produced within the cell, where it protects biomembranes, proteins, enzymes and nucleic acids against dehydration caused by high temperature, salt concentration, and low water content.

bitop AG introduced Ectoin® for human use to serve as a moisturizer and anti-aging element for dermatological applications. After many years of R&D and collaboration with research institutes, the compound has been validated for application as a naturally-derived ingredient to alleviate and treat e.g. allergic symptoms. In fact, the company recently filed for different patents with the United States Patent and Trademark Office (USPTO) to use Ectoin® in treating allergic rhinitis, asthma, COPD, atopic dermatitis, and in the prophylactic treatment of vascular leaks. In Europe, these patents have been granted by the European Patent Office.

Apart from its clinically-proven properties in dermatology and allergy treatments, Ectoin® can be used to treat nasal, mouth, and throat discomfort due to coughing or the common cold. It can also address dryness of the mucosa in the nose and of the conjunctiva in the eye in sicca syndromes due to its superior water-binding and membrane-stabilising features that enable rehydration and stabilisation of mucosal layers.

"With the World Allergy Organization (WAO) highlighting allergies as a global public health issue affecting approximately 30-40 percent of the population, especially children, bitop AG's breakthrough allergy products are uniquely positioned to address the needs of a burgeoning market," said Vin Nee, Frost & Sullivan Industry Analyst. "Importantly, the company's formulations are preservative-free, and clinically proven to be safe and reliable. Many Ectoin®-containing products have already received CE registration within the EU."

bitop AG is also the pioneer in the industrial bioprocessing of extremolytes. Its continuous production technique for Ectoin® uses Halomonas elongata (H. elongata) bacteria. The process avoids human errors or cross-contamination during the transfer of processing materials, which could occur in conventional bioreactor processing procedures.

"bitop AG's progressive efforts in the validation of Ectoin®-containing medical devices for treating allergic symptoms and the exploration in using Ectoin® in treating symptoms of different other diseases will continue to strengthen the company's product line," opined Vin Nee.

In recognition, Frost & Sullivan is pleased to present bitop AG with the 2013 European New Product Innovation Award in the extremolyte therapeutics market for allergies. Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leverage leading-edge technologies. The award recognizes the value added features/benefits of the product and the increased ROI it offers customers, which in turn increases customer acquisition and overall market penetration potential.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About bitop AG

bitop AG, a German company founded in 1993, is focused on the development of Ectoin®-containing medical devices. Besides its Ectoin Allergy Products it is offering also other products such as nasal sprays for the symptomatic treatment of acute rhinosinusitis and rhinitis sicca, eye drops for the treatment of symptoms in case of dry eye syndrome or creams which alleviate symptoms in case of inflammatory skin diseases to distributors worldwide. bitop AG is worldwide the only manufacturer of Ectoin®.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:        Gain access to visionary innovation


Dr. Silke Behne
Business Development Manager
bitop AG
T: +49 (0) 2302 / 91440-14

Kristina Menzefricke
Best Practices Group
Frost & Sullivan
T: +44 (0) 207 9157862

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan
2. Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon
3. Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market
4. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
5. Frost & Sullivan Presents 2012 Clinical Diagnostics Company of the Year Award to GenPath Diagnostics of BioReference Laboratories, Inc.
6. Infectious Disease Prevalence and New Strains Appearing Each Year Makes a Watertight Case for Clinical Laboratory Testing, Finds Frost & Sullivan
7. Laboratory Decision Makers Cautiously Optimistic about Funding Conditions, Finds Frost & Sullivan
8. Frost & Sullivan Recognizes MicroProtein Technologies for its Path-Breaking Production Technology for Recombinant Proteins in Bacteria
9. The Legends that Contributed to Silicon Valleys Eminence Assemble for Frost & Sullivans Growth, Innovation and Leadership 2012 Congress
10. Frost & Sullivan: Asia Pacific Infectious Disease Diagnostics Market Grows as Economies Boom and Countries Become Image Conscious
11. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... year and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual ... November 2015, where ISPE hosted the largest number of attendees in more than ...
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):